BL Pharmtech
Key metrics
Earnings
| Revenue, Q3 2026 | ₩1.1bn |
|---|---|
| Revenue QoQ | +56.8% |
| Revenue YoY | +23.4% |
| Operating income, Q3 2026 | ₩32m |
| Operating income QoQ | Turned to profit |
| Operating income YoY | Turned to profit |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 2 |
|---|---|
| DART filings, previous 3 months | 3 |
Insider transactions
| Open-market buys, last 12 months (shares) | 159,774 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩76m |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 159,774 shares |
| Insiders who bought, last 12 months | 1 |
Insider transactions (last 12 months)
Open-market buys: 159,774 shares (₩76m). Open-market sells: 0 shares (₩0). Net open-market buying: +159,774 shares. Insiders who bought: 1.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Jan 20, 2026 | Park Yeong-cheol (Registered director, 10%+ shareholder) | Open-market buy | +14,000 shares | ₩578 | ₩8m | |
| Jan 15, 2026 | Park Yeong-cheol (Registered director, 10%+ shareholder) | Open-market buy | +15,000 shares | ₩529 | ₩8m | |
| Jan 14, 2026 | Park Yeong-cheol (Registered director, 10%+ shareholder) | Open-market buy | +50,000 shares | ₩515 | ₩26m | |
| Jan 13, 2026 | Park Yeong-cheol (Registered director, 10%+ shareholder) | Open-market buy | +20,700 shares | ₩453 | ₩9m | |
| Jan 12, 2026 | Park Yeong-cheol (Registered director, 10%+ shareholder) | Open-market buy | +60,074 shares | ₩420 | ₩25m |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩6.5bn | -₩2.8bn |
| 2024 | ₩8.8bn | -₩3.2bn |
| 2023 | ₩24.5bn | -₩6.8bn |
Filing timeline
-
BL Pharmtech equity acquisition/disposal: Gwangdong Health Bio
BL Pharmtech filed an equity acquisitions and disposals report on Nov 5, 2026. The target company named in the filing is Gwangdong Health Bio Co., Ltd.